Spruce Biosciences Profit Margin

Spruce Biosciences posts a profit margin of -Infinity% as of March 2026. That compares with -14.24% in the prior-year period — down Infinity% year over year. That is below the Healthcare sector average of 15.58%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Spruce Biosciences's profit margin was -14.24%. The latest reading is -Infinity% — a Infinity% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.58% is typical. Spruce Biosciences's -Infinity% is lower that level. That is roughly Infinity% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Spruce Biosciences's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -Infinity% as of March 2026; use YoY and peer views to separate noise from signal.

Context for SPRB's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.58%), and (3) consistency with growth and profitability. This page covers the first two; Spruce Biosciences's other metric pages and overview cover the third.